• Statistically significant improvements are seen for mortality, hospitalization, progression, recovery, cases, and viral clearance. 17 studies from 11 independent teams in 4 different countries show statistically significant improvements in isolation (8 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 60% [42‑73%] improvement. Results are similar for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies. Results are consistent with early treatment being more effective than late treatment. • Results are robust — in exclusion sensitivity analysis 12 of 21 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.• Efficacy is variant dependent. In Vitro studies suggest a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary]. • While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 29% of casirivimab/imdevimab studies show zero events in the treatment arm. Multiple treatments are typically used in combination, and other treatments may be more effective.• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.• All data to reproduce this paper and sources are in the appendix.